HisRoom.net Blog Men's Health Major Updates to Prostate Cancer Screening: What Men Need to Know About New Guidelines
Men's Health

Major Updates to Prostate Cancer Screening: What Men Need to Know About New Guidelines

Major Updates to Prostate Cancer Screening: What Men Need to Know About New Guidelines

Written By: John Fernandez

The American Cancer Society now recommends regular prostate cancer screening for men starting at age 50, with earlier and more frequent testing for those at higher risk.

For millions of American men, deciding when to begin prostate cancer screening has often involved weighing the potential benefits of early detection against the risks of unnecessary testing and treatment. Now, a major update from the American Cancer Society (ACS) offers clearer guidance.

In recommendations released last week, the ACS calls for regular prostate-specific antigen (PSA) blood testing every two years for men at average risk between ages 50 and 69. Black men and men with a strong family history of prostate cancer should begin annual screening at age 45.

The new recommendations represent a significant shift from the organization’s previous guidance, issued in 2010, which emphasized discussing the advantages and disadvantages of screening with a healthcare provider, rather than directly recommending routine testing.

‘Stronger’ Focus on PSA-based Screening

Rohan Garje, M.D., chief of Genitourinary Medical Oncology at Baptist Heath Herbert Wertheim Cancer Institute, says the updated guidelines reflect a better understanding of how to identify potentially dangerous prostate cancers without exposing every patient to unnecessary procedures.

“The updated ACS recommendations still emphasize shared decision-making and a discussion of the potential benefits and harms of PSA screening,” Dr. Garje explains. “However, the language is now stronger in favor of offering PSA-based screening to appropriate patients, reflecting growing evidence that screening can reduce the risk of advanced prostate cancer and prostate cancer mortality.”

The change reflects growing evidence that PSA screening can reduce deaths from prostate cancer, along with improvements in how physicians evaluate abnormal results and manage cancers that may never become life-threatening.

According to the ACS, an estimated 333,830 American men will be diagnosed with prostate cancer in 2026, and approximately 36,320 will die from the disease. Prostate cancer is the second-leading cause of cancer death among U.S. men.

“More current evidence reveals that PSA screening lowers prostate cancer deaths and advanced-stage diagnoses,” said David Taub, M.D., urologist and director of urologic oncology and director of urologic robotic surgery at the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital. “We also now have better ways to avoid unnecessary biopsies and overtreatment of low-risk prostate cancer.”

“Black men and men with a strong family history have a higher absolute risk of clinically significant prostate cancer, tend to develop disease earlier, and have a greater risk of prostate-cancer mortality.”
Rohan Garje, M.D., chief of Genitourinary Medical Oncology at Baptist Heath Herbert Wertheim Cancer Institute.

Why Prostate Cancer Screening Recommendations Have Changed

Shared decision-making means that patients and healthcare providers discuss screening options together, considering personal risk factors, overall health and individual preferences.

Ashley Marton, M.D., hematologist and medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute Boynton Beach location, part of Baptist Health Cancer Care, also emphasizes the importance of advances in prostate cancer detection and treatment.

Dr. Marton says the changes are “driven by decades of new survival data and safer ways to diagnose and manage the disease.”

Importantly, the updated guidelines do not mean that every abnormal screening result requires a biopsy or that every prostate cancer diagnosis requires immediate treatment.

Instead, physicians now have additional tools to distinguish potentially aggressive cancers from slower-growing forms that may never threaten a patient’s health.

“The PSA is a simple blood test. If the blood test is abnormal, doctors will then repeat it and possibly order complementary non-invasive testing to establish further details.”
Ashley Marton, M.D., hematologist and medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute Boynton Beach location, part of Baptist Health Cancer Care

“The PSA is a simple blood test,” Dr. Marton emphasizes. “If the blood test is abnormal, doctors will then repeat it and possibly order complementary non-invasive testing to establish further details.”

Who Should Be Screened, and at What Age?

The updated ACS recommendations establish different screening schedules based on age, family history and other risk factors.

Ages 50–69, average risk: PSA blood test every two years

Ages 45–69, Black men: Annual PSA screening

Ages 45–69, strong family history: Annual PSA screening

Ages 45–69, non-Black men with one first-degree relative diagnosed at age 65 or older: PSA screening every two years

Ages 70–74: Individualized decision with a healthcare provider

Ages 75–79: Generally not recommended; exceptions may be considered for very healthy men

Ages 80 and older: Screening not recommended

The ACS also advises against screening men whose life expectancy is less than 10 years.

For men in their 70s, Dr. Garje emphasizes that screening decisions should reflect individual circumstances, rather than age alone.

“Finally, for men ages 70 to 74, screening is not automatically discontinued,” he said. “The decision should be individualized through shared decision-making, taking into account overall health, life expectancy, prior PSA results, and the patient’s preferences.”

For men with certain inherited genetic risks or relatives diagnosed unusually early, screening may need to begin before age 45. Those decisions should be made with a healthcare provider.

Why Black Men and Those With a Family History Face Greater Risks

One of the most significant changes involves earlier and more frequent screening for men at increased risk.

According to the ACS, Black men experience a 67 percent higher incidence of prostate cancer and nearly twice the mortality rate compared with White men.

These differences reflect a combination of factors, including disparities in healthcare access, timely diagnosis and treatment, as well as possible biological influences.

“Black men and men with a strong family history have a higher absolute risk of clinically significant prostate cancer, tend to develop disease earlier, and have a greater risk of prostate-cancer mortality,” Dr. Garje explains.

A strong family history generally means having at least one first-degree relative — a father, brother or son — diagnosed with prostate cancer before age 65, or multiple first-degree relatives diagnosed at any age.

Dr. Marton also points to the importance of inherited risk. Screening may need to begin earlier, she explains, “if their relative was diagnosed very early in life or if there is a known genetic predisposition.”

A genetic predisposition means inheriting a gene change that increases the likelihood of developing certain cancers. Men with known inherited cancer-related mutations should discuss an individualized screening plan with their physicians.

“Low-risk cancers can often be watched safely through active surveillance rather than treated right away. That’s how we find the aggressive cancers while sparing men unnecessary procedures.”
David Taub, M.D., urologist and director of urologic oncology and director of urologic robotic surgery at the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital.

Understanding the PSA Test and What an Elevated Result Means

The PSA test is a relatively simple blood test that measures prostate-specific antigen, a protein produced by the prostate gland. Higher PSA levels can indicate prostate cancer, but they can also result from noncancerous conditions, including an enlarged prostate or inflammation of the gland.

An elevated PSA result, therefore, does not automatically mean cancer is present. The ACS recommends repeating an elevated PSA test within two weeks to three months before making further decisions.

Under the updated guidelines, elevated PSA thresholds warranting repeat testing are:

  • Ages 45–69: 3.0 nanograms per milliliter (ng/mL) or higher.
  • Ages 70–74: 6.5 ng/mL or higher.

These levels are not diagnostic cutoffs for cancer. They indicate when additional evaluation is appropriate. Dr. Garje says one of the most important improvements in prostate cancer screening involves what happens after an abnormal result.

“In the past, an elevated PSA often led more directly to prostate biopsy,” Dr. Garje explains. “Today, an abnormal PSA is generally followed by additional risk assessment, which may include repeat PSA testing, validated biomarker tests, prostate MRI, and consideration of other clinical risk factors before proceeding to biopsy.”

A biomarker test looks for measurable biological signs associated with cancer risk. Magnetic resonance imaging, or MRI, produces detailed images that can help physicians identify suspicious areas within the prostate. These additional tests can help determine whether a biopsy — a procedure that removes small tissue samples for examination — is necessary.

“This allows us to better identify patients who are most likely to have clinically significant prostate cancer while reducing unnecessary biopsies,” Dr. Garje says.

The PSA test remains the primary screening tool. A digital rectal examination, in which a physician feels the prostate for abnormalities, is not recommended as a stand-alone screening method.

“PSA is just one piece of the puzzle,” said Dr. Marton. “Prostate cancer comes in different forms, ranging from low risk to high risk … and more aggressive forms. The new screening will help us identify those with aggressive forms earlier — offering the best care to patients, no matter what type of form we find, and the most options available with our new current tech technologies.”

Dr. Taub points out the importance of consulting with your primary care physician regarding any concerns about initial prostate screening.

“Before you begin, your physician should make sure you understand the benefits, limitations, and potential harms related to prostate cancer screening,” said Dr. Taub. “The PSA is only the first step.” 

Finding Aggressive Cancers While Avoiding Unnecessary Treatment

Not all prostate cancers behave the same way.

Some grow rapidly and may spread beyond the prostate, making early diagnosis and treatment particularly important. Others develop slowly and may never cause symptoms or threaten a man’s life.

This distinction has long presented a challenge for screening programs.

Although PSA testing can identify cancer before symptoms develop, it can also uncover slow-growing tumors that might never require treatment. This can lead to overdiagnosis and overtreatment.

Treatments such as surgery and radiation can carry risks, including urinary incontinence, erectile dysfunction and other complications.

The updated ACS recommendations emphasize using more precise diagnostic tools and carefully selecting patients who need immediate treatment.

Active Surveillance for Low-Risk Prostate Cancer

For men diagnosed with low-risk prostate cancer, active surveillance is increasingly an important option.

“Similarly, if a biopsy detects very low-risk or low-risk prostate cancer, many patients can be managed safely with active surveillance rather than immediate surgery or radiation,” Dr. Garje said.

Active surveillance involves closely monitoring the cancer through scheduled PSA tests, medical evaluations, imaging and sometimes repeat biopsies, rather than immediately proceeding with surgery or radiation. Treatment can begin if there are signs that the cancer is becoming more aggressive.

“By combining better risk stratification before biopsy with active surveillance after diagnosis, we can preserve the benefit of detecting aggressive cancers early while minimizing unnecessary procedures and overtreatment,” Dr. Garje explains.

Risk stratification refers to evaluating clinical findings and test results to estimate how likely a cancer is to grow, spread or cause harm. Dr. Marton similarly emphasizes that prostate cancer exists along a spectrum, from less aggressive forms to cancers requiring prompt treatment.

The goal is to identify aggressive cancers early while allowing men with lower-risk disease to avoid unnecessary interventions whenever medically appropriate.

Ultimately, repeated PSAs, an MRI and/or validated biomarker test help decide whether a biopsy is needed. “Low-risk cancers can often be watched safely through active surveillance rather than treated right away,” said Dr. Taub. “That’s how we find the aggressive cancers while sparing men unnecessary procedures.”

What Men Should Do Now

For men approaching age 50, the updated ACS recommendations provide a clearer reason to discuss prostate cancer screening during a routine medical appointment. Those who are Black, have close relatives diagnosed with prostate cancer or have known inherited cancer risks should consider having that conversation earlier.

Learn more aboutprostate cancer screenings.

Featured Providers

Rohan Garje, MD

Rohan Garje, MD

Rohan Garje, MD, FASCO, is a nationally renowned medical oncologist and the chief of genitourinary medical oncology at Baptist Health Herbert Wertheim Cancer Institute. Dr. Garje specializes in the treatment of prostate, kidney, bladder, testicular and penile cancer. Dr Garje has significant expertise in the design of novel investigator-initiated clinical trials and has served as the principal investigator for numerous phase I, II and III clinical trials. He focuses on providing precision oncology care utilizing targeted therapy, hormonal therapy, immunotherapy, radioligand therapy and chemotherapy. Dr. Garje is an internationally published leader in cancer research. He has amassed over 70 peer reviewed publications in prestigious journals, such as Lancet Oncology, Journal of Clinical Oncology, Journal of Immunotherapy for Cancer, Radiology and Clinical Cancer Research.  At the Institute, he leads a team of medical oncologists actively involved in clinical research bringing industry-leading treatments to patients with genitourinary cancers. Before joining Miami Cancer Institute in 2022, Dr. Garje served as an associate professor of medicine in hematology and oncology at the University of Iowa/Holden Comprehensive Cancer Center.Dr. Garje is also the chair for the castration-resistant prostate cancer guidelines committee for the American Society of Clinical Oncology. He leads the committee’s work in reviewing research and writing guidelines for prostate cancer treatment. Dr. Garje serves on the editorial board for Current Problems in Cancer and is a reviewer for multiple journals including Journal of Clinical Oncology and Journal of Oncology Practice. Dr. Garje is passionate about providing individual care to each patient because each has a unique journey. He takes time to listen to patients and walks with them throughout their treatment. When he is not treating patients, Dr. Garje enjoys spending time with his family and traveling, always with a camera in hand. He is fluent in English, Hindi, Telugu and Marathi.

Ashley Marton, MD

Ashley Marton, M.D.C.M., is a hematologist and medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute Boynton Beach location, part of Baptist Health Cancer Care. She treats a broad range of solid tumors and hematologic conditions and has a dedicated clinical focus on breast, prostate and colon cancers.

Dr. Marton is committed to staying at the leading edge of advances in oncology, including new therapies that can help prolong survival and offer curative potential. She translates the latest scientific developments into evidence-based, individualized treatment plans for her patients.

Dr. Marton earned her medical degree at McGill University in Montreal. She also completed her internal medicine residency, hematology residency and medical oncology residency at McGill University.

Before joining Baptist Health, Dr. Marton was a hematologist and medical oncologist at Hôpital de la Cité-de-la-Santé in Laval, Québec, Canada, and an assistant professor in the Department of Medicine at the University of Montreal. She also served as site director for breast cancer and gastrointestinal cancers.

Dr. Marton is actively involved in clinical research and has served as a principal investigator and sub-investigator for numerous oncology clinical trials. Her research interests include improving access to new therapies through clinical trials, integrating new cancer treatments into care, optimizing medical resources and exploring the role of artificial intelligence in medicine.

Dr. Marton’s care philosophy is rooted in collaboration, patient education and shared decision-making. She views the physician-patient relationship as an equal partnership and takes time to ensure patients understand their diagnosis, prognosis and treatment options. By aligning clinical evidence with each patient’s values, lifestyle and goals, she helps patients make confident, informed decisions about their care.

Dr. Marton is fluent in English and French. When she is not treating patients, she enjoys spending time with her family, playing tennis, doing yoga and staying fit.

David Andrew Taub, MD

David Taub, M.D., FACS, is a board-certified urologist and director of urologic oncology and director of urologic robotic surgery at the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital. Dr. Taub specializes in treating urologic cancer.Prior to joining Lynn Cancer Institute, Dr. Taub was on staff at Boca Raton Regional Hospital. He is a fellow of the American College of Surgeons and a member of the American Medical Association and the American Urological Association. Dr. Taub also holds a Master of Business Administration from the University of Michigan Ross School of Business. Dr. Taub’s research has been published in peer-reviewed publications, including Urology, the Journal of Urology, BJU International, Neurourology and Urodynamics, and the Journal of Clinical Oncology. He has also presented at numerous industry events and conferences. Dr. Taub’s care philosophy is to use a patient-centric, holistic approach. He believes patient treatment is a team effort that includes the physician, patient, their family and other specialized physicians, when necessary. His mission is to provide patients with safe, comfortable, quality care to achieve the best outcomes. When he is not treating patients, Dr. Taub enjoys being active through running, biking, traveling and spending time with family. He particularly enjoys being outside in the Florida sunshine.
Learn More

Exit mobile version